S&P Futures
3,942.75 +6.00 (+0.15%) Dow Futures
33,652.00 +27.00 (+0.08%) Nasdaq Futures
11,535.00 +25.50 (+0.22%) Russell 2000 Futures
1,811.40 +3.40 (+0.19%) Crude Oil
72.93 +0.92 (+1.28%) Gold
1,794.30 -3.70 (-0.21%)
FUJIFILM Holdings Corporation (FUJIY)
Chart Events
Performance Outlook
| Previous Close | 51.76 |
| Open | 51.61 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 51.34 - 51.61 |
| 52 Week Range | 44.30 - 78.45 |
| Volume | |
| Avg. Volume | 57,460 |
| Market Cap | 20.905B |
| Beta (5Y Monthly) | 0.32 |
| PE Ratio (TTM) | 13.45 |
| EPS (TTM) | 3.83 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.85 (1.63%) |
| Ex-Dividend Date | Sep 29, 2022 |
| 1y Target Est | 59.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for FUJIY
Related Research
- FUJIFILM HOLDINGS CORPORATION ABDC: Lowering target price to $86.00BELDEN INC has an Investment Rating of BUY; a target price of $86.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.RatingFair ValueEconomic Moat8 days agoArgus Research
- Zacks
FUJIFILM's (FUJIY) Q2 Earnings and Revenues Increase Y/Y
FUJIFILM (FUJIY) second-quarter performance gains from strong revenue growth in Medical Systems, Electronic Materials and Imaging business segment.
- The Wall Street Journal
Fujifilm Drops Anti-Covid-19 Pill Avigan, Once Hailed as Silver Bullet
Fujifilm Holdings Corp. said it was giving up on its antiviral drug Avigan to treat Covid-19, more than two years after Japan’s prime minister hailed the pill.
- Benzinga
Once Favored By Late Shinzo Abe, Japan Culls Development On Repurposed COVID-19 Treatment
Fujifilm Holdings Corp (OTC: FUJIY) (OTC: FUJIF) has discontinued the development of its anti-influenza drug, Avigan (favipiravir), for use as a therapeutic drug against COVID-19. In 2021, Fujifilm Toyama Chemical began a phase 3 clinical trial in Japan with a target enrollment of 316 subjects to confirm Avigan's efficacy in preventing the progression to severe symptoms in COVID-19 patients who have not yet been vaccinated. However, enrollment was terminated at 84 subjects in March 2022 followin
